Strontium-90 is a "bone seeker" that exhibits biochemical behavior similar to calcium, the next lighter group 2 element. After entering the organism, most often by ingestion with contaminated food or water, about 70–80% of the dose gets excreted. Virtually all remaining strontium-90 is deposited in bones and bone marrow, with the remaining 1% remaining in blood and soft tissues. Its presence in bones can cause bone cancer, cancer of nearby tissues, and leukemia. Exposure to Sr can be tested by a bioassay, most commonly by urinalysis.
The biological half-life of strontium-90 in humans has variously been reported as from 14 to 600 days, 1000 days, 18 years, 30 years and, at an upper limit, 49 years. The wide-ranging published biological half life figures are explained by strontium's complex metabolism within the body. However, by averaging all excretion paths, the overall biological half life is estimated to be about 18 years.
The elimination rate of strontium-90 is strongly affected by age and sex, due to differences in bone metabolism.
Together with the caesium isotopes Cs and Cs, and the iodine isotope I, it was among the most important isotopes regarding health impacts after the Chernobyl disaster.
As strontium has an affinity to the calcium-sensing receptor of parathyroid cells that is similar to that of calcium, the increased risk of liquidators of the Chernobyl power plant to suffer from primary hyperparathyroidism could be explained by binding of strontium-90.